← Leaderboards
Trevor Levin
Convergent Genomics, Inc.
$6,160,047
Attributed
$6,160,047
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $2.9M · FY2016–21$5M$3.8M$2.5M$1.3M$0
'16
'17
'18
'19
'20
'21
Funding mix
By agency
NIH$6,160,047 · 1
By mechanism
R44$6,160,047 · 1
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Cancer Patient”
- David Heimbrook · Leidos Biomedical Research, Inc.$436,176,488
- Larry Arthur$370,429,903
- Norman Wolmark · Nsabp Foundation, Inc.$324,028,859
- Gregory H Reaman · National Childhood Cancer Foundation$270,366,096
- Leonard Freedman · Leidos Biomedical Research, Inc.$268,085,841
- Richard A Gibbs · Baylor College Of Medicine$240,560,484
Research focus
Cancer PatientBasePerformanceValidationSamplingOperative Surgical ProceduresTumorSpecificityUrineRecurrenceMolecularSmall Business Innovation Research GrantMalignant Neoplasm Of Urinary BladderMalignant NeoplasmsCancer DiagnosisCostDiagnosisCystoscopyMonitorProceduresDesignCytologyDiagnosticSensitivity And Specificity
Grant awards (6)
Expanded Clinical Validation & Commercial Launch of the UriSeq Platform for Bladder Cancer$1,635,549
R44 · FY2021 · CA · contact PI
Expanded Clinical Validation & Commercial Launch of the UriSeq Platform for Bladder Cancer$1,875,550
R44 · FY2020 · CA · contact PI
Improved diagnostic sensitivity for rapid COVID-19 testing using Enhanced Preservation Media$999,975
R44 · FY2020 · CA · contact PI
SBIR grant application to develop and commercialize a urine based medical diagnostic for the detection of bladder cancer recurrence.$670,314
R44 · FY2018 · CA · contact PI
SBIR grant application to develop and commercialize a urine based medical diagnostic for the detection of bladder cancer recurrence.$686,883
R44 · FY2017 · CA · contact PI
SBIR grant application to develop and commercialize a urine based medical diagnostic for the detection of bladder cancer recurrence.$291,776
R44 · FY2016 · CA · contact PI